Found: 4 articles

Article Edition
Romashkina N.V., Klishina M.V., Carabina E.V.
Frequency and spectrum of PIK3CA mutations in hormone-dependent HER2-negative breast cancer: a single-center experience
№4 / 2024
R.V. Orlova, M.I. Gluzman, A.A. Vakhitova
Possibilities of overcoming hormone resistance in patients with metastatic HR+ HER2- breast cancer using the drug alpelisib in various subgroups in real clinical practice
№11 / 2023
V.F. Semiglazov, P.V. Krivorotko, A.V. Komyakhov, T.Yu. Semiglazova, L.P. Gigolaeva, T.T. Tabagua, M.D. Kazantseva, A.P. Tergoeva, D.G. Ulrikh, M.V. Chervyak, V.V. Klimenko, N.S. Amirov, E.K. Zhiltsova, V.V. Semiglazov
The role of alpelisib in the treatment of PIK3CA – a mutated breast cancer
№11-12 / 2022
O.O. Gordeeva (1), I.P. Ganshina (1), V.I. Garifullina (2)
Dermatological toxity of alpelisib: clinical experience and review of current guidelines
№7 / 2021


Бионика Медиа